Traders bet on Orexigen diet drug success; Biotech vet named CEO of Receptos;

 @FierceBiotech: Pearl Therapeutics drug beats blockbuster COPD drug in PhIIb. News | Follow @FierceBiotech

 @JohnCFierce: GSK is confirming to me that SRT501 is dead. Weak efficacy, renal risks. Now moving on to other formulations. Report | Follow @JohnCFierce

> Despite some big doubts about Orexigen's reception next week by an FDA advisory panel, traders on Wall Street are betting that the company will succeed in getting an endorsement for its obesity drug. Story

> Receptos named biotech vet Faheem Hasnain as its new CEO. Hasnain was most recently president and CEO of Facet Biotech. Receptos release

> Novartis has filed a counterclaim against Gatekeeper Pharmaceuticals seeking a declaraory judgment that it owns the rights to the lung cancer drug WZ4002 and other compounds developed at Dana-Farber. Report

> Lebanon, NH-based Adimab, a 2010 Fierce 15 company, has raised an additional $4 million. Story

> South San Francisco-based Hana Biosciences is officially changing its name today to Talon Therapeutics. Story

And Finally... Daniel Kelly, M.D., and his colleagues at Sanford-Burnham Medical Research Institute Lake Nona have unveiled a surprising new model for studying muscle function: the couch potato mouse. Release

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”